Description
The feasibility assessment noted TREM2’s therapeutic potential but the debate was incomplete regarding selective recognition of pathological conformations. This selectivity is crucial to avoid disrupting normal protein function while clearing toxic species.
Source: Debate session sess_SDA-2026-04-01-gap-9137255b (Analysis: SDA-2026-04-01-gap-9137255b)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:55.540041+00:00”, “resolution_summary”: “Resolved by hypothesis h-3460f820: TREM2-Mediated Selective Aggregate Clearance Pathway. Supporting evidence includes debate sess_SDA-2026-04-12-gap-debate-20260410-112812-429571d2.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-3460f820”, “title”: “TREM2-Mediated Selective Aggregate Clearance Pathway”, “score”: 0.439, “reason”: “11 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-01-gap-9137255b”, “target_gene”: “TREM2”, “target_pathway”: “TREM2 → SYK → PI3K/mTOR phagocytic signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.584, “confidence_score”: 0.5, “status”: “proposed”, “pubmed_evidence_ids”: [“29899446”, “31398344”, “32719508”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112812-429571d2”, “title”: “The theorist proposed this novel approach to enable safe agonism across disease stages, but no evidence exists for such selective pathway activation. This represents a critical gap for developing safer TREM2 therapeutics.\n\nSource: Debate session sess_SDA-2026-04-01-gap-001 (Analysis: SDA-2026-04-01-gap-001)”, “score”: 0.483, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-, trem2”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112812-429571d2”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-01-gap-001”, “title”: “The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.”, “score”: 0.361, “reason”: “3 token overlaps; entity overlap: sda-2026-04-01-, trem2”, “analysis_id”: “SDA-2026-04-01-gap-001”, “quality_score”: 0.57, “status”: “completed”, “target_artifact_id”: “SDA-2026-04-01-gap-001”, “target_artifact_type”: “analysis”}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112945-6a9ce0a3”, “title”: “The debate revealed that DNAJB6 evidence is limited to polyglutamine aggregation, with no direct testing of heterologous cross-seeding inhibition. This fundamental gap undermines the universal inhibitor hypothesis and requires specific cross-seeding assays.\n\nSource: Debate session sess_SDA-2026-04-01-gap-9137255b (Analysis: SDA-2026-04-01-gap-9137255b)”, “score”: 0.358, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112945-6a9ce0a3”, “quality_score”: 0.79, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-100405-abac24bc”, “title”: “The debate proposed biphasic TREM2 modulation but couldn’t define when to switch from inhibition to activation. The Skeptic noted AD lacks discrete temporal phases, making this critical for any temporal therapeutic strategy.\n\nSource: Debate session sess_SDA-2026-04-10-trem2-ad (Analysis: trem2-ad)”, “score”: 0.358, “reason”: “7 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-100405-abac24bc”, “quality_score”: 0.3, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112915-df7f8ad0”, “title”: “The debate revealed that stress granules can be both neuroprotective and pathological, but the molecular switches governing this transition remain unknown. Understanding these mechanisms is critical for timing therapeutic interventions targeting phase separation dynamics.\n\nSource: Debate session sess_SDA-2026-04-01-gap-v2-68d9c9c1 (Analysis: SDA-2026-04-01-gap-v2-68d9c9c1)”, “score”: 0.345, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112915-df7f8ad0”, “quality_score”: 0.86, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}